Evrysdi - direct healthcare professional communication (DHPC)

risdiplam

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Evrysdi 0.75 mg/mL powder for oral solution (risdiplam): omission of mandatory labelling statement in the EU product label and summary of product characteristics

Dissemination date: 21/08/2025

Key facts

• Medicine name:
  Evrysdi
• Active substance:
  risdiplam
• Therapeutic area (MeSH):
  Muscular Atrophy, Spinal
• DHPC type:
  Quality defect
• Human ATC codes:
  M09AX10
• Dissemination date:
  21/08/2025